Get started
OCUGEN INCOCUGEN INCOCUGEN INC

OCUGEN INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

OCGN trade ideas

Trading Idea - #OcugenMy trading idea for - #Ocugen - BUY Entry: 0.95 USD Target: 8.00 USD (+720% profit) Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Institutional Trading of Ocugen A number of large investors have recently added their stakes in OCGN. JPMorgan Chase & Co. increased its holdings in Ocugen by 20.9% during the first quarter. JPMorgan Chase & Co. now owns 4,015,742 shares of the company's stock worth $13,251,000 after buying an additional 693,786 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Ocugen during the first quarter worth about $47,000. Cetera Investment Advisers purchased a new stake in Ocugen during the first quarter worth about $50,000. Vanguard Group Inc. increased its holdings in Ocugen by 2.8% during the first quarter. Vanguard Group Inc. now owns 10,906,557 shares of the company's stock worth $35,991,000 after buying an additional 301,063 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Ocugen during the first quarter worth about $34,000. Hedge funds and other institutional investors own 21.50% of the company's stock. Ocugen Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
NASDAQ:OCGNLong
by Traderherz-Analytics
2
$OCGN Ocugen Inc Long term PTs 16 - 21 - 180 and higherNASDAQ:OCGN Ocugen Inc Long term PTs 16 - 21 - 180 and higher Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
NASDAQ:OCGNLong
by BADQOMOCAWGOWLD
2
OCUGENThe wyckoff method is a very accurate method, There are many variations and purposes--soley to liquidate others or take shares from retail or weak hands, To sell of shares to FOMO traders or breakout traders. Liquidating Other institutions or create misleading Bullish signals and prices to entice investors etc, etc. the real skill is identifying the purpose of price movement, its likely targets of short term liquidity, and long term goals in correspondence to News.
NASDAQ:OCGNShort
by Integrity_Investments
5
OCGN Earnings Tomorrow! $15 Strike Price calls! WOWOcugen is a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines. They announced yesterday that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results tomorrow, May 6, before the market opens. As soon as i saw the news, there were also 764 calls with a $15 strike price expiring jan 20 in the options chain. they paid a 11.5k premium paid for the calls. Considering that the price is 2.25, such an impressive out of the money bunch of calls made me think it was an insider information about something that could be released tomorrow. On 2/28/2022 S. Ramakanth from HC Wainwright gave a Buy rating for OCGN and a price target of $8.00, while Robert LeBoyer from Noble Financialhas a $15.00 price target. I`m extremely bullish on OCGN earnings tomorrow. Looking forward to read your opinion about it.
NASDAQ:OCGNLong
by TopgOptions
5
Ocugen ocgn Strong candles Big target 10.28hi all bro... OCUGEN firts target. 5.05 second 5.87 . and 6.10 big target:10.28 *****important- ***** thin line above price is the first target. thin line below price is support.. stop point. Fibonacci correction between the highest price and lowest fiat in the chart area are thick lines.. thick lines are hard support and hard resistances.. main target in fallen assets is the green line . decline in peak assets main target green line ********** thnks goodluck.. always stoploss ..
NASDAQ:OCGN
by Takaro
1
Ocugen $OCGN - The Roulette TheoryHere is an example of the "Roulette Theory" that I have created by myself. The Roulette Theory is very simple, it is a theory that works on the probability of the candle colours. When a roulette table spins, you have 3 options, Red, Black and Green ( ZERO). The probability of have many REDs is much lower than having more equal amounts of RED and Black. When a Roulette table has many REDs, it is in your favour mathematically and statistically to bet that a different colour appears. The same principal is used here in the "Roulette Theory". The Roulette Theory was created by Missed A Million in 2013 and has a high probability of success. In order to be most effective, the last candle close must be a spinning top doji (Cross Shaped) in the same colour as all other candlesticks.
NASDAQ:OCGNLong
by missedamillion
2
OCUGEN CALLS IDEA!! $7.5 Dec 22 Best Vaccine pandemic play!! $Ocugen has just proven to have a vaccine that ( Covaxin) can neutralize both Omnicron ( most infectious ) and the Delta variant( most violent ). $Ocugen has seen a beating! Last Quarter the company dropped nearly 50% from previous highs . I'm expecting a return to those highs some time late spring/early summer. I think $3 is the lowest we can go but, to me its all upside from here! $Ocugen could also cause some serious problems for Over- Exposed short sellers. With T-35 filings piling up and over 25% of the Float in Short interest , this could see a monumental increase in price. ## The play ## Great news behind a great company, professionals have a price target at $10 which is a 110% gain from current levels!!! My personal Price target is the $20-$25 range. Recently, I've opened some Dec 22 call options on OCUGEN at $7.5 ! Target: 1 | Target: 2 | Target: 3 $11 | $16.50 | $25
NASDAQ:OCGNLong
by FxChulo